gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

GRB2-related adaptor protein 2

GRID, Gads, Mona
This gene encodes a member of the GRB2/Sem5/Drk family. This member is an adaptor-like protein involved in leukocyte-specific protein-tyrosine kinase signaling. Like its related family member, GRB2-related adaptor protein (GRAP), this protein contains an SH2 domain flanked by two SH3 domains. This protein interacts with other proteins, such as GRB2-associated binding protein 1 (GAB1) and the SLP-76 leukocyte protein (LCP2), through its SH3 domains. Transcript variants utilizing alternative polyA sites exist. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, SLP-76, Grb2, SET, LAT
Papers on GRID
Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.
Chan et al., Xi'an, China. In Leukemia, Jan 2016
Surface plasmon resonance analysis of mutations at these residues with predicted differential partner interactions showed increased affinity for ligand CD86 (residue D124) and increased affinity for intracellular adaptor proteins GRB2 and GADS/GRAP2 (residue T195).
The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Stępniak et al., Warsaw, Poland. In Expert Opin Drug Saf, Jan 2016
AREAS COVERED: Regorafenib, an oral multitargeted inhibitor with activity against multiple kinases including KIT, RET, RAF1, BRAF, angiogenesis (VEGFR, TIE-2) and those involved in tumor microenvironment (PDGFR and FGFR) was introduced after the successful Phase III GRID (GIST - Regorafenib In progressive Disease) clinical trial.
Quantitative Correlation of Conformational Binding Enthalpy with Substrate Specificity of Serine Proteases.
Liedl et al., In J Phys Chem B, Jan 2016
We determined sub-pocket interaction potentials with GRID for static X-ray structures and an in silico generated ensemble of conformations.
Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
Tortorella et al., Bari, Italy. In Curr Top Med Chem, Dec 2015
In particular, FLAP, a program based on GRID molecular interaction fields, was used to analyze the ligand-protein interactions: molecular shape and hydrogen bond acceptor groups strongly influence the binding according to the ligand-based modeling, while the aromatic interactions are better identified by the structure-based study.
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Witkin et al., United Kingdom. In Neuropsychopharmacology, Dec 2015
Once daily oral dosing of LY2940094 at 40 mg for 8 weeks vs placebo provided some evidence for an antidepressant effect based on the change from baseline to week 8 in the GRID-Hamilton Depression Rating Scale-17 item total score, although the predefined POC efficacy criterion (probability of LY2940094 being better than placebo⩾88%) was not met (82.9%).
The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells.
Knobeloch et al., Freiburg, Germany. In Nat Immunol, Sep 2015
Here we identified the ubiquitin-specific protease USP8 as a regulatory component of the T cell antigen receptor (TCR) signalosome that interacted with the adaptor Gads and the regulatory molecule 14-3-3β.
Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Keating et al., Auckland, New Zealand. In Drugs, Jun 2015
Based on the findings of the phase III GRID clinical trial, approval for regorafenib has been expanded to include the treatment of advanced gastrointestinal stromal tumours (GISTs) following the failure of imatinib and sunitinib.
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
Tournigand et al., Reims, France. In Target Oncol, Jun 2015
Single-agent regorafenib administered as a 160-mg daily dose for the first 21 days of a 28-day cycle is approved for use in patients with pretreated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST) progressing on imatinib and sunitinib, following publication of data from the phase III CORRECT and GRID studies respectively.
Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
Ojha et al., Abu Dhabi, United Arab Emirates. In Drug Des Devel Ther, 2014
EGCG and curcumin showed binding to the active site residues with a low GRID score, which may be a potential inhibitor of HMGR.
Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Walko et al., United States. In Ann Pharmacother, 2013
Phase III GRID (Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib) trial data revealed a progression-free survival benefit in imatinib- and sunitinib-resistant GIST patients (4.8 vs 0.9 months; P < .0001).
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
GRID study investigators et al., Boston, United States. In Lancet, 2013
BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression.
[A review of face illusions].
Kitaoka, Kyoto, Japan. In Brain Nerve, 2012
The "gaze illusion" or the illusion of eye direction includes the Wollaston illusion, the luminance-induced gaze shift, the Bogart illusion, the eye-shadow-dependent gaze illusion, the Mona Lisa effect, etc. "Face inversion effects" refer to the Thatcher illusion, the fat face-thin illusion, underestimation of the upright face, the nose-shortening illusion of the inverted face, etc. "Geometrical illusions" include the Lee-Freire illusion, Yang's iris illusion, overestimation of the farther eye, the eye-shadow-dependent eye-size illusion, etc. "Reversible figures" contain the whole-part reversible figure, Rubin's vase-face illusion, or hybrid images.
Gads regulates the expansion phase of CD8+ T cell-mediated immunity.
Yankee et al., Kansas City, United States. In J Immunol, 2011
Data show that the primary function of Gads is to regulate the sensitivity of the TCR to Ag ligation.
The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway.
Kolch et al., Glasgow, United Kingdom. In Cell Signal, 2010
The results show that Bcr-Abl regulates the actin cytoskeleton and non-apoptotic membrane blebbing via a GADS/Slp-76/Nck1 adaptor protein pathway.
Histidine domain-protein tyrosine phosphatase interacts with Grb2 and GrpL.
Tanase, Bucureşti, Romania. In Plos One, 2009
Histidine domain-protein tyrosine phosphatase interacts with Grb2 and GrpL
Expression of the Grb2-related RET adapter protein Grap-2 in human medullary thyroid carcinoma.
Karges et al., München, Germany. In Cancer Lett, 2009
Consistent Grap-2 expression suggests a specific role for this adaptor in human medullary thyroid carcinoma, while qualitative alterations do not appear to influence RET signaling
Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2.
Watson et al., Birmingham, United Kingdom. In J Thromb Haemost, 2008
Gads plays a key role in linking the adapter LAT to SLP-76 in response to weak activation of GPVI and CLEC-2 whereas LAT is required for full activation over a wider range of agonist concentrations.
Targeted cleavage of signaling proteins by caspase 3 inhibits T cell receptor signaling in anergic T cells.
Macian et al., United States. In Immunity, 2008
In anergic T cells, activated caspase 3 associated to the plasma membrane, where it cleaved and inactivated proteins such as the Grb2-related adaptor downstream of shc (GADS) and the guanine-nucleotide exchange factor Vav1, causing a blockade in TCR signaling.
Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses.
Tan et al., Houston, United States. In Nat Immunol, 2007
HPK1 is a Ste20-related serine-threonine kinase that inducibly associates with the adaptors SLP-76 and Gads after T cell receptor (TCR) signaling.
A point mutation in CD28 distinguishes proliferative signals from survival signals.
Rottapel et al., Toronto, Canada. In Nat Immunol, 2001
This is because it permits CD28 to recruit SH2-containing signaling molecules, including phosphoinositide 3 kinase, Grb2 and Gads.
share on facebooktweetadd +1mail to friends